WT1

Summary

Gene Symbol: WT1
Description: Wilms tumor 1
Alias: AWT1, GUD, NPHS4, WAGR, WIT-2, WT33, Wilms tumor protein
Species: human
Products:     WT1

Top Publications

  1. Hohenstein P, Hastie N. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 2006;15 Spec No 2:R196-201 pubmed
    ..Over the years, many apparently contradictory findings and functions have been ascribed to the protein product of the WT1 tumour suppressor gene...
  2. Vicent S, Chen R, Sayles L, Lin C, Walker R, Gillespie A, et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest. 2010;120:3940-52 pubmed publisher
    ..of functional genomics and mouse genetics, we identified a role for the transcription factor Wilms tumor 1 (WT1) as a critical regulator of senescence and proliferation downstream of oncogenic KRAS signaling...
  3. Royer Pokora B, Beier M, Henzler M, Alam R, Schumacher V, Weirich A, et al. Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. Am J Med Genet A. 2004;127A:249-57 pubmed
    We report here 24 new Wilms tumor (WT) patients with germline WT1 alterations and a synopsis of our own previously described and literature cases in whom age of tumor-onset, gender, and laterality were known...
  4. Kim M, McGarry T, O Broin P, Flatow J, Golden A, Licht J. An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proc Natl Acad Sci U S A. 2009;106:11154-9 pubmed publisher
    b>WT1, a critical regulator of kidney development, is a tumor suppressor for nephroblastoma but in some contexts functions as an oncogene...
  5. Hollink I, van den Heuvel Eibrink M, Zimmermann M, Balgobind B, Arentsen Peters S, Alders M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 2009;113:5951-60 pubmed publisher
    Wilms tumor 1 (WT1) mutations have recently been identified in approximately 10% of adult acute myeloid leukemia (AML) with normal cytogenetics (CN-AML) and are associated with poor outcome...
  6. Ho P, Kuhn J, Gerbing R, Pollard J, Zeng R, Miller K, et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol. 2011;29:704-11 pubmed publisher
    To analyze the prevalence and clinical implications of Wilms' tumor 1 (WT1) single nucleotide polymorphism (SNP) rs16754 in the context of other prognostic markers in pediatric acute myeloid leukemia (AML)...
  7. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, et al. Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci. 2004;95:822-7 pubmed
    ..These results may indicate that the W T1 gene plays an important role in tumorigenesis of primary astrocytic tumors. ..
  8. Morrison D, Kim M, Berkofsky Fessler W, Licht J. WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression. Mol Cancer Res. 2008;6:1225-31 pubmed publisher
    In its role as a tumor suppressor, WT1 transactivates several genes that are regulators of cell growth and differentiation pathways...
  9. Amin E, Oltean S, Hua J, Gammons M, Hamdollah Zadeh M, Welsh G, et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 2011;20:768-80 pubmed publisher
    ..Mutations in WT1, the Wilms' tumor suppressor gene, suppress VEGF(165)b and cause abnormal gonadogenesis, renal failure, and Wilms' ..

More Information

Publications102 found, 100 shown here

  1. Dallosso A, Hancock A, Malik S, Salpekar A, King Underwood L, Pritchard Jones K, et al. Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer. RNA. 2007;13:2287-99 pubmed
    ..b>WT1 is a well-characterized developmental gene that is mutated in Wilms' tumor (WT) and acute myeloid leukaemia (AML) ..
  2. Rauscher J, Beschorner R, Gierke M, Bisdas S, Braun C, Ebner F, et al. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. J Clin Pathol. 2014;67:556-61 pubmed publisher
    The zinc finger transcription factor WT1 is expressed in astrocytic neoplasms and therefore is a potential target of immunotherapy in brain tumours...
  3. Hartkamp J, Carpenter B, Roberts S. The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi. Mol Cell. 2010;37:159-71 pubmed publisher
    The Wilms' tumor suppressor protein WT1 functions as a transcriptional regulator of genes controlling growth, apoptosis, and differentiation...
  4. Ohno S, Dohi S, Ohno Y, Kyo S, Sugiyama H, Suzuki N, et al. Immunohistochemical detection of WT1 protein in endometrial cancer. Anticancer Res. 2009;29:1691-5 pubmed
    The Wilms' tumor gene WT1 is overexpressed in various kinds of solid tumors. However, it remains unclear whether WT1 plays a pathophysiological role in endometrial cancer...
  5. Garrido Ruiz M, Rodriguez Pinilla S, Perez Gomez B, Rodriguez Peralto J. WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis. J Cutan Pathol. 2010;37:542-8 pubmed publisher
    b>WT1, first recognized as a tumor suppressor gene involved in the development of Wilms' tumor, may have apparently contradictory findings and functions...
  6. Oue T, Uehara S, Yamanaka H, Takama Y, Oji Y, Fukuzawa M. Expression of Wilms tumor 1 gene in a variety of pediatric tumors. J Pediatr Surg. 2011;46:2233-8 pubmed publisher
    Wilms tumor 1 (WT1) gene is overexpressed in many types of neoplasms, thus suggesting that WT1 has oncogenic properties. Therefore, WT1 is a molecular target for cancer therapy...
  7. Gaidzik V, Schlenk R, Moschny S, Becker A, Bullinger L, Corbacioglu A, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 2009;113:4505-11 pubmed publisher
    To evaluate the incidence and clinical impact of WT1 gene mutations in younger adult patients with cytogenetically normal acute myeloid leukemia (CN-AML), sequencing of the complete coding region was performed in diagnostic samples from ..
  8. Smolen G, Vassileva M, Wells J, Matunis M, Haber D. SUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Res. 2004;64:7846-51 pubmed
    ..The WT1 tumor suppressor encodes a four-zinc finger protein with distinct splicing isoforms...
  9. Tuna M, Chavez Reyes A, Tari A. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene. 2005;24:1648-52 pubmed
    High levels of the Wilms' Tumor 1 (WT1) protein and mRNA had been associated with aggressive phenotypes of breast tumors. Here we report that the HER2/neu oncogene increases WT1 expression...
  10. Barbolina M, Adley B, Shea L, Stack M. Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer. 2008;112:1632-41 pubmed publisher
    ..primary and metastatic ovarian carcinoma samples was employed to detect expression of Wilms tumor gene protein 1 (WT1)...
  11. Candoni A, Tiribelli M, Toffoletti E, Cilloni D, Chiarvesio A, Michelutti A, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol. 2009;82:61-8 pubmed publisher
    b>WT1 overexpression is described in several oncological diseases including acute myeloid leukemia (AML)...
  12. Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Göhring G, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2010;28:578-85 pubmed publisher
    ..assessed the prognostic impact of a known single nucleotide polymorphism (SNP) located in the mutational hotspot of WT1 in patients with cytogenetically normal acute myeloid leukemia (CN-AML) in the context of other prognostic markers...
  13. Zhao X, Jin S, Zhu H, Xu L, Liu D, Chen H, et al. Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012;47:499-507 pubmed publisher
    To evaluate the prognostic significance of Wilms' tumor gene 1 (WT1) expression for monitoring minimal residual disease and predicting relapse in patients with acute leukemia (AL) following allogeneic hematopoietic SCT (allo-HSCT), the ..
  14. Cedres S, Montero M, Zamora E, Martinez A, Martinez P, Farinas L, et al. Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma. Clin Transl Oncol. 2014;16:776-82 pubmed publisher
    Calretinin and Wilms' tumor gene (WT1) are mesothelial markers routinely used to confirm the diagnosis of malignant pleural mesothelioma (MPM)...
  15. Hou H, Huang T, Lin L, Liu C, Chen C, Chou W, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115:5222-31 pubmed publisher
    The impact of WT1 mutations in acute myeloid leukemia (AML) is not completely settled. We aimed to determine the clinical implication of WT1 mutation in 470 de novo non-M3 AML patients and its stability during the clinical course...
  16. Wu C, Zhu W, Qian J, He S, Wu C, Chen Y, et al. WT1 promotes invasion of NSCLC via suppression of CDH1. J Thorac Oncol. 2013;8:1163-9 pubmed publisher
    The Wilms' tumor gene (WT1) has been identified as an oncogene in many malignant diseases, and aberrant WT1 expression has been linked to development, progression, and prognosis of non-small-cell lung cancer (NSCLC)...
  17. Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T, et al. Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene. 2006;25:4217-29 pubmed
    The WT1 gene is overexpressed in human primary leukemia and a wide variety of solid cancers. The WT1 gene is alternatively spliced at two sites, yielding four isoforms: 17AA(+)KTS(+), 17AA(+)KTS(-), 17AA(-)KTS(+), and 17AA(-)KTS(-)...
  18. Goodfellow S, Rebello M, Toska E, Zeef L, Rudd S, Medler K, et al. WT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell line. Biochem J. 2011;435:113-25 pubmed publisher
    The Wilms' tumour suppressor WT1 (Wilms' tumour 1) is a transcriptional regulator that plays a central role in organogenesis, and is mutated or aberrantly expressed in several childhood and adult malignancies...
  19. Nomdedeu J, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, et al. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia. 2013;27:2157-64 pubmed publisher
    We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients...
  20. Han Y, San Marina S, Liu J, Minden M. Transcriptional activation of c-myc proto-oncogene by WT1 protein. Oncogene. 2004;23:6933-41 pubmed
    The Wilms' tumor 1 gene (WT1) plays an essential role in urogenital development and malignancy...
  21. Depping R, Schindler S, Jacobi C, Kirschner K, Scholz H. Nuclear transport of Wilms' tumour protein Wt1 involves importins ? and ?. Cell Physiol Biochem. 2012;29:223-32 pubmed publisher
    Wilms' tumour protein, Wt1, is a zinc finger molecule, which is required for normal embryonic development. Mutations of the WT1 gene can give rise to childhood cancer of the kidneys...
  22. Amini Nik S, Hohenstein P, Jadidizadeh A, Van Dam K, Bastidas A, Berry R, et al. Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors. Int J Cancer. 2005;114:202-8 pubmed
    ..It has been shown that the Wnt signaling pathway interacts with Wilms' tumor gene 1 (WT1) in normal kidney development and plays a role in the genesis of some Wilms' tumors...
  23. Timar J, Meszaros L, Orosz Z, Albini A, Raso E. WT1 expression in angiogenic tumours of the skin. Histopathology. 2005;47:67-73 pubmed
    To determine the expression of WT1 in endothelial proliferations and tumours. Endothelial cells are derived from angioblasts which differentiate into bone marrow stem cells (BMSC)...
  24. Gannon A, Kinsella B. The Wilms' tumour suppressor protein WT1 acts as a key transcriptional repressor of the human thromboxane A2 receptor gene in megakaryocytes. J Cell Mol Med. 2009;13:4571-86 pubmed publisher
    ..mobility shift assays and supershift assays demonstrated that each of the GC elements can bind Egr1 and WT1 in vitro, chromatin immunoprecipitations established that WT1 is the factor predominantly bound to each of the ..
  25. Miglino M, Colombo N, Pica G, Grasso R, Clavio M, Bergamaschi M, et al. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2011;52:1961-9 pubmed publisher
    ..prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with ..
  26. McCarty G, Awad O, Loeb D. WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J Biol Chem. 2011;286:43634-43 pubmed publisher
    b>WT1 is a zinc finger transcription factor expressed at high levels in many types of solid tumors, and high WT1 expression is an adverse prognostic factor. How WT1 contributes to tumor growth and influences prognosis remains unclear...
  27. Marcet Palacios M, Ulanova M, Duta F, Puttagunta L, Munoz S, Gibbings D, et al. The transcription factor Wilms tumor 1 regulates matrix metalloproteinase-9 through a nitric oxide-mediated pathway. J Immunol. 2007;179:256-65 pubmed
    ..in the 5' flanking region of the MMP-9 gene containing binding sites for the transcription factor Wilms tumor 1 (WT1)...
  28. Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer. 2009;115:3719-27 pubmed publisher
    Wilms tumor 1 (WT1) is a transcription factor that is overexpressed in most acute myeloid leukemias (AMLs)...
  29. Spassov B, Stoimenov A, Balatzenko G, Genova M, Peichev D, Konstantinov S. Wilms' tumor protein and FLT3-internal tandem duplication expression in patients with de novo acute myeloid leukemia. Hematology. 2011;16:37-42 pubmed publisher
    Bone marrow samples of 30 patients with de novo adult acute myeloid leukemia (AML) were analyzed for Wt1 and FLT3-internal tandem duplication (FLT3-ITD) expression measured by western blot and reverse transcription-polymerase chain ..
  30. Liu Z, Yamanouchi K, Ohtao T, Matsumura S, Seino M, Shridhar V, et al. High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer. Anticancer Res. 2014;34:2331-40 pubmed
    The aim of the present study was to evaluate the correlation between WT1 expression levels and clinical features, to investigate the prognostic value of WT1 expression and to use lentiviral constructs to examine whether overexpression of ..
  31. Brett A, Pandey S, Fraizer G. The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells. Mol Cancer. 2013;12:3 pubmed publisher
    ..We have previously reported the presence of one such transcription factor, WT1 in high Gleason grade prostate tumor tissues, and its absence in non-neoplastic or benign prostatic hyperplasia ..
  32. Choi E, Yun J, Jeon E, Won H, Ko Y, Kim S. Prognostic significance of RSPO1, WNT1, P16, WT1, and SDC1 expressions in invasive ductal carcinoma of the breast. World J Surg Oncol. 2013;11:314 pubmed publisher
    ..ductal carcinoma, we studied the correlations between SDC1 expression and related gene expressions (RSPO1, WNT1, WT1, and P16)...
  33. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101:13885-90 pubmed
    The Wilms' tumor gene WT1 is overexpressed in leukemias and various types of solid tumors, and the WT1 protein was demonstrated to be an attractive target antigen for immunotherapy against these malignancies...
  34. Kim M, Mason J, Li C, Berkofsky Fessler W, Jiang L, Choubey D, et al. A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16. Neoplasia. 2008;10:69-78 pubmed
    The Wilms tumor gene (WT1) is mutated or deleted in patients with heredofamilial syndromes associated with the development of Wilms tumors, but is infrequently mutated in sporadic Wilms tumors...
  35. Morrison A, Viney R, Saleem M, Ladomery M. New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes. Am J Physiol Renal Physiol. 2008;295:F12-7 pubmed publisher
    ..These include WAGR (for Wilms tumor, aniridia, genitourinary anomalies, and mental retardation), and Frasier and Denys-Drash syndromes...
  36. Willasch A, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H, et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia. 2009;23:1472-9 pubmed publisher
    ..Although hyperexpression of Wilms' tumor (WT1) gene transcript has been frequently proposed as an MRD marker in AML, wide comparability of the various methods ..
  37. Cilloni D, Renneville A, Hermitte F, Hills R, Daly S, Jovanovic J, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27:5195-201 pubmed publisher
    ..One proposed marker is the Wilms tumor gene WT1, which is overexpressed in most patients with AML, thus providing a putative target for immunotherapy, although in ..
  38. Candoni A, Toffoletti E, Gallina R, Simeone E, Chiozzotto M, Volpetti S, et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant. 2011;25:308-16 pubmed publisher
    b>WT1 is well-known to be a panleukemic marker that is expressed in 90% of acute myeloid leukemias (AML)...
  39. Kreidberg J. WT1 and kidney progenitor cells. Organogenesis. 2010;6:61-70 pubmed
    ..Wilms' tumor-1 (WT1), that encodes a transcription factor and RNA-binding protein, was one of the first tumor suppressor genes ..
  40. Singh A, Mishra A, Ylaya K, Hewitt S, Sharma K, Saxena S. Wilms tumor-1, claudin-1 and ezrin are useful immunohistochemical markers that help to distinguish schwannoma from fibroblastic meningioma. Pathol Oncol Res. 2012;18:383-9 pubmed publisher
    ..000), <. 001], Claudin-1 [0.857(0.782, 0.932), <0.001] and ezrin [0.792(0.700,0.884),<0.001]. WT-1, Claudin-1 and Ezrin may be potentially useful immunohistochemical adjuncts to EMA and S100 that differentiate SCHW from FM...
  41. Choi Y, Lee J, Hur E, Kang M, Kim S, Lee J, et al. Single nucleotide polymorphism of Wilms' tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. Ann Hematol. 2012;91:671-677 pubmed publisher
    A recent study from Germany showed that WT1 single nucleotide polymorphism (SNP) rs16754 was an independent prognostic factor in cytogenetically normal acute myeloid leukemia (CN-AML)...
  42. Vadasz Z, Shasha Lavsky H, Nov Y, Bejar J, Lurie M, Tadmor T, et al. Wilms' tumor gene 1: a possible new proangiogenic factor in Hodgkin lymphoma. Appl Immunohistochem Mol Morphol. 2013;21:177-80 pubmed publisher
    Wilms' tumor gene 1 (WT1) was recently found to play a role in solid and hematologic malignancies and serves as a marker of prognosis and minimal residual disease in acute leukemia. WT1 was also found to be involved in tumor angiogenesis...
  43. Toska E, Campbell H, Shandilya J, Goodfellow S, Shore P, Medler K, et al. Repression of transcription by WT1-BASP1 requires the myristoylation of BASP1 and the PIP2-dependent recruitment of histone deacetylase. Cell Rep. 2012;2:462-9 pubmed publisher
    The Wilms' tumor 1 protein WT1 is a transcriptional regulator that is involved in cell growth and differentiation. The transcriptional corepressor BASP1 interacts with WT1 and converts WT1 from a transcriptional activator to a repressor...
  44. Xu C, Wu C, Xia Y, Zhong Z, Liu X, Xu J, et al. WT1 promotes cell proliferation in non-small cell lung cancer cell lines through up-regulating cyclin D1 and p-pRb in vitro and in vivo. PLoS ONE. 2013;8:e68837 pubmed publisher
    The Wilms' tumor suppressor gene (WT1) has been identified as an oncogene in many malignant diseases such as leukaemia, breast cancer, mesothelioma and lung cancer...
  45. Ho P, Alonzo T, Gerbing R, Kuhn J, Pollard J, Hirsch B, et al. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group. Pediatr Blood Cancer. 2014;61:81-8 pubmed publisher
    b>WT1 is aberrantly over-expressed in most cases of AML. We recently demonstrated that WT1 SNP rs16754 correlates with favorable outcome and high diagnostic WT1 expression in childhood AML...
  46. Toska E, Roberts S. Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1). Biochem J. 2014;461:15-32 pubmed publisher
    The WT1 (Wilms' tumour 1) gene encodes a zinc finger transcription factor and RNA-binding protein that direct the development of several organs and tissues...
  47. Dallosso A, Hancock A, Brown K, Williams A, Jackson S, Malik K. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. Hum Mol Genet. 2004;13:405-15 pubmed
    ..Here we report that a novel alternative WT1 transcript, AWT1, is co-expressed with WT1 in renal and haematopoietic cells...
  48. Srichai M, Konieczkowski M, Padiyar A, Konieczkowski D, Mukherjee A, Hayden P, et al. A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. J Biol Chem. 2004;279:14398-408 pubmed
    Glomerular podocyte differentiation state is critical for filtration barrier function and is regulated by WT1, a zinc finger transcription factor...
  49. Dupont J, Wang X, Marshall D, Leitao M, Hedvat C, Hummer A, et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol. 2004;94:449-55 pubmed
    With the exception of ovarian serous carcinoma, Wilms tumor suppressor gene (WT1) expression in common gynecologic carcinomas has not been described in detail...
  50. Ariyaratana S, Loeb D. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;9:1-17 pubmed
    ..to its loss playing a pivotal role in the development of a childhood kidney malignancy, the Wilms tumour 1 gene (WT1) has emerged as an important factor in normal and malignant haematopoiesis...
  51. Coosemans A, Nik S, Caluwaerts S, Lambin S, Verbist G, van Bree R, et al. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer. 2007;43:1630-7 pubmed
    Overexpression of Wilms' tumour gene (WT1) has been proven in several tumours. Previous research of our group on the cell cycle of uterine leiomyosarcoma (LMS) and carcinosarcoma (CS) suggested a possible role for WT1...
  52. Wagner N, Panelos J, Massi D, Wagner K. The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch. 2008;455:839-47 pubmed
    Expression of the Wilms' tumor suppressor WT1 has been demonstrated in a variety of tumors and tumor cell lines, e.g., in breast cancer and melanoma cell lines...
  53. Navakanit R, Graidist P, Leeanansaksiri W, Dechsukum C. Growth inhibition of breast cancer cell line MCF-7 by siRNA silencing of Wilms tumor 1 gene. J Med Assoc Thai. 2007;90:2416-21 pubmed
    ..Define the role of Wilms tumor 1 gene (WT1) in breast cancer oncogenesis using RNAi...
  54. Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S, et al. Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol. 2008;32:701-11 pubmed
    Wilms' tumor gene WT1 is overexpressed in leukemia and various types of solid tumors and plays an important role in leukemogenesis and tumorigenesis...
  55. Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008;93:921-4 pubmed publisher
    The Wilms' tumor gene WT1 is a reliable marker for minimal residual disease assessment in acute leukemia patients...
  56. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008;26:5429-35 pubmed publisher
    To determine the clinical relevance of Wilms' tumor 1 (WT1) gene mutations in acute myeloid leukemia (AML) with normal karyotype (NK)...
  57. Noronha S, Farrar J, Alonzo T, Gerbing R, Lacayo N, Dahl G, et al. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;53:1136-9 pubmed publisher
    b>WT1 is a transcription factor that is aberrantly overexpressed in acute and chronic leukemias...
  58. Miyawaki S, Hatsumi N, Tamaki T, Naoe T, Ozawa K, Kitamura K, et al. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma. 2010;51:1855-61 pubmed publisher
    We retrospectively analyzed the potential of Wilms' tumor gene 1 (WT1) mRNA levels in peripheral blood for predicting the prognosis of 50 patients with AML. After achieving complete remission (CR), 34 patients (69...
  59. Ochi T, Fujiwara H, Okamoto S, An J, Nagai K, Shirakata T, et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood. 2011;118:1495-503 pubmed publisher
    ..the clinical application of siTCR gene therapy for human leukemia, we examined in detail the efficacy and safety of WT1-siTCR-transduced T cells...
  60. Andersson C, Li X, Lorenz F, Golovleva I, Wahlin A, Li A. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Diagn Mol Pathol. 2012;21:225-33 pubmed publisher
    Wilms tumor gene 1 (WT1) expression has been suggested as an applicable minimal residual disease marker in acute myeloid leukemia (AML). We evaluated the use of this marker in 43 adult AML patients...
  61. Little S, Hanks S, King Underwood L, Jones C, Rapley E, Rahman N, et al. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. J Clin Oncol. 2004;22:4140-6 pubmed
    Constitutional WT1 mutations in patients with Wilms' tumor (WT) have specifically been associated with genitourinary abnormalities, such as cryptorchidism and hypospadias...
  62. Burwell E, McCarty G, Simpson L, Thompson K, Loeb D. Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Oncogene. 2007;26:3423-30 pubmed
    The role of WT1 (Wilm's tumor suppressor gene) in breast cancer is controversial, with evidence for both tumor-promoting and tumor-suppressing activities...
  63. Summers K, Stevens J, Kakkas I, Smith M, Smith L, MacDougall F, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia. 2007;21:550-1; author reply 552 pubmed
  64. Sera T, Hiasa Y, Mashiba T, Tokumoto Y, Hirooka M, Konishi I, et al. Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur J Cancer. 2008;44:600-8 pubmed publisher
    Wilms' tumour 1 gene (WT1) was originally isolated as a tumour-suppressor gene...
  65. Paschka P, Marcucci G, Ruppert A, Whitman S, Mrozek K, Maharry K, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2008;26:4595-602 pubmed publisher
    To analyze the prognostic impact of Wilms' tumor 1 (WT1) gene mutations in cytogenetically normal acute myeloid leukemia (CN-AML)...
  66. Han Y, Yang L, Suarez Saiz F, San Marina S, Cui J, Minden M. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells. Mol Cancer Res. 2008;6:1347-55 pubmed publisher
    ..Wilms' tumor 1 suppressor gene (WT1) is a clinically useful marker that is associated with poor prognosis in breast cancer patients; its high level ..
  67. Tosello V, Mansour M, Barnes K, Paganin M, Sulis M, Jenkinson S, et al. WT1 mutations in T-ALL. Blood. 2009;114:1038-45 pubmed publisher
    ..In addition, we identified deletions and associated mutations in the WT1 tumor suppressor gene in 2 of 9 samples. Subsequent analysis showed WT1 mutations in 28 of 211 (13...
  68. Nowakowska Kopera A, Sacha T, Florek I, Zawada M, Czekalska S, Skotnicki A. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Leuk Lymphoma. 2009;50:1326-32 pubmed
    Wilms' tumor gene 1 (WT1) gene expression was analyzed in 32 patient with acute myeloid leukemia (AML) and 18 with acute lymphoblastic leukemia (ALL) to investigate whether it could serve as a MRD marker...
  69. Becker H, Maharry K, Radmacher M, Mrozek K, Metzeler K, Whitman S, et al. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica. 2011;96:1488-95 pubmed publisher
    The alleles of the Wilms tumor 1 (WT1) polymorphism rs16754 harbor adenine (A) or guanine (G). Recently, rs16754 has been reported to affect the outcome of patients with cytogenetically normal acute myeloid leukemia...
  70. Bejrananda T, Phukaoloun M, Boonpipattanapong T, Wanitsuwan W, Kanngern S, Sangthong R, et al. WT1 expression as an independent marker of poor prognosis in colorectal cancers. Cancer Biomark. 2010;8:35-42 pubmed publisher
    b>WT1 has been proven to be a prognostic marker and molecular target in various human cancers. In this study, we aimed to investigate the prognostic role of WT1 in colorectal cancers (CRCs)...
  71. Hayashi S, Oji Y, Kanai Y, Teramoto T, Kitaichi M, Kawaguchi T, et al. Low Wilms' tumor gene expression in tumor tissues predicts poor prognosis in patients with non-small-cell lung cancer. Cancer Invest. 2012;30:165-71 pubmed publisher
    We elucidated the relationship between prognosis of non-small-cell lung cancer (NSCLC) and Wilms' tumor gene (WT1) mRNA expression in tumor tissue...
  72. Scattone A, Serio G, Marzullo A, Nazzaro P, Corsi F, Cocca M, et al. High Wilms' tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma. Histopathology. 2012;60:472-81 pubmed publisher
    To evaluate the use of the Wilms' tumour gene (WT1) marker and histomorphological parameters as indicators of prognosis in malignant peritoneal mesothelioma (MPM)...
  73. Parenti R, Puzzo L, Vecchio G, Gravina L, Salvatorelli L, Musumeci G, et al. Immunolocalization of Wilms' Tumor protein (WT1) in developing human peripheral sympathetic and gastroenteric nervous system. Acta Histochem. 2014;116:48-54 pubmed publisher
    Developmental expression of Wilms' tumor gene (WT1) and protein is crucial for cell proliferation, apoptosis, differentiation and cytoskeletal architecture regulation...
  74. Katuri V, Gerber S, Qiu X, McCarty G, Goldstein S, Hammers H, et al. WT1 regulates angiogenesis in Ewing Sarcoma. Oncotarget. 2014;5:2436-49 pubmed
    Angiogenesis is required for tumor growth. WT1, a protein that affects both mRNA transcription and splicing, has recently been shown to regulate expression of vascular endothelial growth factor (VEGF), one of the major mediators of ..
  75. Kim A, Park E, Kim K, Lee J, Shin D, Kim J, et al. Prognostic significance of WT1 expression in soft tissue sarcoma. World J Surg Oncol. 2014;12:214 pubmed publisher
    Soft tissue sarcomas (STS) are rare. We evaluated the WT1 protein expression level in various types of STS and elucidated the value of WT1 as a prognostic factor and a possible therapeutic target...
  76. Lovell M, Xie C, Xiong S, Markesbery W. Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Brain Res. 2003;983:84-96 pubmed
    Wilms' tumor suppressor (WT1), a 52- to 54-kda transcription factor, is the gene product of Wilms' tumor 1 (wt1), one of at least three genes involved in the development of a pediatric kidney cancer...
  77. Carpenter B, Hill K, Charalambous M, Wagner K, Lahiri D, James D, et al. BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1. Mol Cell Biol. 2004;24:537-49 pubmed
    The Wilms' tumor suppressor protein WT1 is a transcriptional regulator that plays a key role in the development of the kidneys...
  78. Barragan E, Cervera J, Bolufer P, Ballester S, Martin G, Fernández P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica. 2004;89:926-33 pubmed
    The Wilms' tumor (WT1) gene is overexpressed in patients with most forms of acute leukemia. Several studies have reported the usefulness of quantitative assessment of WT1 expression as a molecular marker of minimal residual disease...
  79. Guo G, Morrison D, Licht J, Quaggin S. WT1 activates a glomerular-specific enhancer identified from the human nephrin gene. J Am Soc Nephrol. 2004;15:2851-6 pubmed
    ..The Wilms tumor suppressor gene (WT1) is a zinc-finger-containing transcription factor that is coexpressed with NPHS1 in differentiated podocytes; gel ..
  80. Srivastava A, Fuchs B, Zhang K, Ruan M, Halder C, Mahlum E, et al. High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res. 2006;12:4237-43 pubmed
    ..Microarray analysis revealed 5.3-fold more expression of WT1 mRNA in osteogenic sarcoma compared with normal bone and >2-fold overexpression in 143B and LM8 cells compared ..
  81. Høgdall E, Christensen L, Kjaer S, Blaakaer J, Christensen I, Gayther S, et al. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study. Gynecol Oncol. 2007;106:318-24 pubmed
    To determine the WT1 expression level in tumor tissues from 774 women with an epithelial ovarian tumor...
  82. Wagner N, Michiels J, Schedl A, Wagner K. The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo. Oncogene. 2008;27:3662-72 pubmed publisher
    ..We showed that the Wilms' tumour suppressor WT1 activates nestin during development. Here we tested whether WT1 might also be involved in tumour angiogenesis...
  83. Furuhata A, Murakami M, Ito H, Gao S, Yoshida K, Sobue S, et al. GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. Leukemia. 2009;23:1270-7 pubmed publisher
    Although oncogenic functions and the clinical significance of Wilms tumor 1 (WT1) have been extensively studied in acute leukemia, the regulatory mechanism of its transcription still remains to be determined...
  84. Becker H, Marcucci G, Maharry K, Radmacher M, Mrozek K, Margeson D, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116:788-92 pubmed publisher
    We previously reported the adverse prognostic impact of Wilms tumor 1 gene (WT1) mutations in younger adult cytogenetically normal acute myeloid leukemia (CN-AML)...
  85. Coosemans A, Van Calster B, Verbist G, Moerman P, Vergote I, Van Gool S, et al. Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma. Int J Gynecol Cancer. 2011;21:302-8 pubmed publisher
    Wilms tumor gene 1 (WT1) contributes to uterine sarcoma tumor biology. In this study, we aimed to clarify the prognostic value of WT1...
  86. Cunningham T, Palumbo I, Grosso M, Slater N, Miles C. WT1 regulates murine hematopoiesis via maintenance of VEGF isoform ratio. Blood. 2013;122:188-92 pubmed publisher
    Mutations in the Wilms tumor suppressor 1 (WT1) gene are as frequent in acute myeloid leukemia (AML) as in nephroblastma and predict poor prognosis. However, the role of WT1 in hematopoiesis remains unclear...
  87. Vidovic K, Ullmark T, Rosberg B, Lennartsson A, Olofsson T, Nilsson B, et al. Leukemia associated mutant Wilms' tumor gene 1 protein promotes expansion of human hematopoietic progenitor cells. Leuk Res. 2013;37:1341-9 pubmed publisher
    The transcription factor Wilms' tumor gene 1 (WT1) is highly expressed in the majority of leukemias, suggesting a role in leukemogenesis...
  88. Rather M, Swamy S, Gopinath K, Kumar A. Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics. J Biol Chem. 2014;289:968-76 pubmed publisher
    The Wilms tumor 1 gene (WT1) can either repress or induce the expression of genes. Inconsistent with its tumor suppressor role, elevated WT1 levels have been observed in leukemia and solid tumors...
  89. Green L, Wagner K, Campbell H, Addison K, Roberts S. Dynamic interaction between WT1 and BASP1 in transcriptional regulation during differentiation. Nucleic Acids Res. 2009;37:431-40 pubmed publisher
    The Wilms' tumour suppressor protein WT1 plays a central role in the development of the kidney and also other organs. WT1 can act as a transcription factor with highly context-specific activator and repressor functions...
  90. Perugorria M, Castillo J, Latasa M, Goñi S, Segura V, Sangro B, et al. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. Cancer Res. 2009;69:1358-67 pubmed publisher
    The Wilms' tumor 1 gene (WT1) encodes a transcription factor involved in cell growth and development. As we previously reported, WT1 expression is hardly detectable in normal hepatic tissue but is induced in liver cirrhosis...
  91. Sitaram R, Degerman S, Ljungberg B, Andersson E, Oji Y, Sugiyama H, et al. Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer. 2010;103:1255-62 pubmed publisher
    Wilms' tumour 1 (WT1) gene was discovered as a tumour suppressor gene. Later findings have suggested that WT1 also can be oncogenic. This complexity is partly explained by the fact that WT1 has a number of target genes.
  92. Gray J, McMillen L, Mollee P, Paul S, Lane S, Bird R, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leuk Res. 2012;36:453-8 pubmed publisher
    b>WT1 levels may be a useful predictor of leukemia free survival (LFS) following treatment of acute myeloid leukemia (AML)...